Caris Life Sciences Q1 Revenue Surges 79% to $216.2M, Achieves Operating Profitability
CAI is trading near its 52-week low of $16.28 (4.4% above the low).
Summary
Caris Life Sciences reported robust first-quarter 2026 results, with revenue surging 79% year-over-year to $216.2 million. The company achieved positive adjusted EBITDA of $26.2 million and, significantly, swung to an operating income of $5.3 million from a substantial loss in the prior year, with net loss narrowing to just $0.5 million. This strong financial performance is complemented by positive operating cash flow of $32.9 million and free cash flow of $22.5 million. These highly material results demonstrate significant operational improvement and growth, particularly as the company's stock has been trading near its 52-week low. The positive momentum follows the recent MolDX approval for its Caris ChromoSeq product and the successful refinancing of a $400 million credit facility, indicating a strengthening business outlook. Investors will now focus on sustained demand for molecular profiling services and the impact of new product launches and AI initiatives on future quarters.
At the time of this announcement, CAI was trading at $17.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $16.28 to $42.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.